From lab to mass production: a policy for enabling the licensing of mRNA vaccines

Frontiers in Public Health

Public Health

Andreas Panagopoulos¹  Katerina Sideri² 

[1] Department of Economics, Knowledge Transfer Office, TECHNIS, University of Crete, Rethymno, Greece;Department of Political Science and History, TECHNIS, Panteion University, Athens, Greece;

关键词: vaccines;    mass production;    WHO academy;    know – how;    barriers to entry;    South African vaccine hub;    technology transfer;   

DOI  :  10.3389/fpubh.2023.1151713

 received in 2023-01-26, accepted in 2023-04-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Using the South African vaccine technology transfer hub supported by the WHO as an example, we show that the know-how needed to move mRNA vaccines from prototype to mass-production acts as an invisible barrier to market entry of mRNA vaccines. Overcoming this barrier relies on scarce human capital. In view of this scarcity and in preparation for the next pandemic, we propose broadening the scope of an existing WHO program, the WHO Academy, so that it coordinates knowledge diffusion initiatives by forming a systematized repository of know-how and a register of experts. As we explain, this proposal has an advantage in overcoming barriers to entry over current approaches of know-how acquisition.

【 授权许可】

Unknown   
Copyright © 2023 Panagopoulos and Sideri.